REFERENCES
1. Mensah GA, Fuster V, Murray CJ, et al. Global burden of cardiovascular diseases and risks, 1990-2022. J Am Coll Cardiol. 2023;82:2350-473.
2. Stark BA, Decleene NK, Desai EC, et al. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. J Am Coll Cardiol. 2025;86:2167-243.
3. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-826.
4. Heusch G. Myocardial ischemia/reperfusion: Translational pathophysiology of ischemic heart disease. Med. 2024;5:10-31.
5. Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43:2549-61.
6. Heusch G. Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol. 2022;117:1.
7. Dauw J, Martens P, Deferm S, et al. Left ventricular function recovery after ST-elevation myocardial infarction: correlates and outcomes. Clin Res Cardiol. 2021;110:1504-15.
8. Yu X, Chen X, Amrute-Nayak M, et al. MARK4 controls ischaemic heart failure through microtubule detyrosination. Nature. 2021;594:560-5.
9. Yu S, Sun Z, Wang X, et al. Mettl13 protects against cardiac contractile dysfunction by negatively regulating C-Cbl-mediated ubiquitination of SERCA2a in ischemic heart failure. Sci China Life Sci. 2023;66:2786-804.
10. Chen Y, Liu S, Liang Y, et al. Single dose of intravenous miR199a-5p delivery targeting ischemic heart for long-term repair of myocardial infarction. Nat Commun. 2024;15:5565.
11. Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25:396-415.
12. Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24:430-47.
13. Han P, Li W, Lin C, et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014;514:102-6.
14. Du H, Zhao Y, Wen J, et al. LncRNA DCRT protects against dilated cardiomyopathy by preventing NDUFS2 alternative splicing by binding to PTBP1. Circulation. 2024;150:1030-49.
15. Zhang Y, Zhang X, Cai B, et al. The long noncoding RNA lncCIRBIL disrupts the nuclear translocation of Bclaf1 alleviating cardiac ischemia-reperfusion injury. Nat Commun. 2021;12:522.
16. Gao R, Wang L, Bei Y, et al. Long noncoding RNA cardiac physiological hypertrophy-associated regulator induces cardiac physiological hypertrophy and promotes functional recovery after myocardial ischemia-reperfusion injury. Circulation. 2021;144:303-17.
17. Liu N, Kataoka M, Wang Y, et al. LncRNA LncHrt preserves cardiac metabolic homeostasis and heart function by modulating the LKB1-AMPK signaling pathway. Basic Res Cardiol. 2021;116:48.
18. Rogala S, Ali T, Melissari M, et al. The lncRNA sweetheart regulates compensatory cardiac hypertrophy after myocardial injury in murine males. Nat Commun. 2023;14:7024.
19. Yang H, Xuan L, Wang S, et al. LncRNA CCRR maintains Ca2+ homeostasis against myocardial infarction through the FTO-SERCA2a pathway. Sci China Life Sci. 2024;67:1601-19.
20. Zhu M, Liu J, Xiao J, et al. Lnc-mg is a long non-coding RNA that promotes myogenesis. Nat Commun. 2017;8:14718.
21. Pinheiro A, Naya FJ. The Key Lnc (RNA)s in cardiac and skeletal muscle development, regeneration, and disease. J Cardiovasc Dev Dis. 2021;8:84.
22. Sweta S, Dudnakova T, Sudheer S, Baker AH, Bhushan R. Importance of long non-coding RNAs in the development and disease of skeletal muscle and cardiovascular lineages. Front Cell Dev Biol. 2019;7:228.
23. Martone J, Mariani D, Desideri F, Ballarino M. Non-coding RNAs shaping muscle. Front Cell Dev Biol. 2020;7:394.
24. Jiao K, Kulessa H, Tompkins K, et al. An essential role of Bmp4 in the atrioventricular septation of the mouse heart. Genes Dev. 2003;17:2362-7.
25. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-91.
26. Deng Y, Xie M, Li Q, et al. Targeting mitochondria-inflammation circuit by β-hydroxybutyrate mitigates HFpEF. Circ Res. 2021;128:232-45.
27. Abelanet A, Camoin M, Rubin S, et al. Increased capillary permeability in heart induces diastolic dysfunction independently of inflammation, fibrosis, or cardiomyocyte dysfunction. Arterioscler Thromb Vasc Biol. 2022;42:745-63.
28. Lian H, Qin Z, Wu M, et al. Contractility detection of isolated mouse papillary muscle using myotronic Myostation‐Intact device. Anim Models Exp Med. 2022;5:445-52.
29. Powers JD, Kirkland NJ, Liu C, et al. Subcellular remodeling in filamin C deficient mouse hearts impairs myocyte tension development during progression of dilated cardiomyopathy. Int J Mol Sci. 2022;23:871.
30. Gan P, Wang Z, Bezprozvannaya S, et al. RBPMS regulates cardiomyocyte contraction and cardiac function through RNA alternative splicing. Cardiovasc Res. 2024;120:56-68.
31. Yamaguchi N, Xiao J, Narke D, et al. Cardiac pressure overload decreases ETV1 expression in the left atrium, contributing to atrial electrical and structural remodeling. Circulation. 2021;143:805-20.
32. Li Y, Dong M, Wang Q, et al. HIMF deletion ameliorates acute myocardial ischemic injury by promoting macrophage transformation to reparative subtype. Basic Res Cardiol. 2021;116:30.
33. Takagawa J, Zhang Y, Wong ML, et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol. 2007;102:2104-11.
34. Brito-Estrada O, Kuwabara Y, Gibson AM, et al. DWORF gene therapy improves cardiac calcium handling and mitochondrial function. Circ Res. 2025;137:1072-88.
35. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
36. Zhou K, Huang J, Liu S, et al. An encyclopedic regulatory and functional atlas of RNA interactomes. Nat Methods. 2026;23:1109-14.
37. Kang J, Tang Q, He J, et al. RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic Acids Res. 2022;50:D326-32.
38. Muppirala UK, Honavar VG, Dobbs D. Predicting RNA-protein interactions using only sequence information. BMC Bioinformatics. 2011;12:489.
39. Wang ET, Cody NA, Jog S, et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell. 2012;150:710-24.
40. Lv C, Alimu X, Xiao X, et al. Somatic NAP1L1 p.D349E promotes cardiac hypertrophy through cGAS-STING-IFN signaling. Nat Commun. 2025;16:3140.
41. Maguy A, Tessier A, Mahendran Y, et al. Anti-TRPV2 autoantibody linked to sudden infant death syndrome. Circulation. 2025;152:81-4.
42. Fan J, Li Z, Lin L, et al. The potential value of long non-coding RNA in molecular diagnosis and forensic identification of heart failure. Vessel Plus. 2026;10:22.
43. Wang J, Chen X, Shen D, et al. A long noncoding RNA NR_045363 controls cardiomyocyte proliferation and cardiac repair. J Mol Cell Cardiol. 2019;127:105-14.
44. Ponnusamy M, Liu F, Zhang Y, et al. Long noncoding RNA CPR (cardiomyocyte proliferation regulator) regulates cardiomyocyte proliferation and cardiac repair. Circulation. 2019;139:2668-84.
45. Bai X, Yang C, Jiao L, et al. LncRNA MIAT impairs cardiac contractile function by acting on mitochondrial translocator protein TSPO in a mouse model of myocardial infarction. Sig Transduct Target Ther. 2021;6:172.
46. Ma T, Qiu F, Gong Y, et al. Therapeutic silencing of lncRNA RMST alleviates cardiac fibrosis and improves heart function after myocardial infarction in mice and swine. Theranostics. 2023;13:3826-43.
47. Shumliakivska M, Fischer A, Muhly-Reinholz M, et al. The long non-coding RNA Snhg15 protects the heart after myocardial infarction. J Mol Cell Cardiol. 2026;210:72-82.
48. Liang X, Liu S, Liu G, et al. LncRNA SNHG15 promotes angiogenesis and improves cardiac repair after myocardial infarction through MiR-665-mediated KDR expression. Cell Mol Life Sci. 2025;82:211.
49. Zhang Y, Jiao L, Sun L, et al. LncRNAZFAS1 as a SERCA2a inhibitor to cause intracellular Ca2+ overload and contractile dysfunction in a mouse model of myocardial infarction. Circ Res. 2018;122:1354-68.
50. Fan J, Li H, Xie R, et al. LncRNA ZNF593-AS alleviates contractile dysfunction in dilated cardiomyopathy. Circ Res. 2021;128:1708-23.
51. Zhao Y, Riching AS, Knight WE, et al. Cardiomyocyte-specific long noncoding RNA regulates alternative splicing of the triadin gene in the heart. Circulation. 2022;146:699-714.
52. Yang L, Deng J, Ma W, et al. Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure. Theranostics. 2021;11:7995-8007.
53. Aksentijevic D, Sedej S, Fauconnier J, et al. Mechano-energetic uncoupling in heart failure. Nat Rev Cardiol. 2025;22:773-97.
55. Lygate CA. Maintaining energy provision in the heart: the creatine kinase system in ischaemia-reperfusion injury and chronic heart failure. Clin Sci. 2024;138:491-514.
56. Ritterhoff J, Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023;20:812-29.
57. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128:1487-513.
58. Paolisso P, Bergamaschi L, Santulli G, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21:77.
59. Cao J, Wei Z, Nie Y, Chen H. Therapeutic potential of alternative splicing in cardiovascular diseases. eBioMedicine. 2024;101:104995.
60. Dixon DM, Choi J, El-Ghazali A, et al. Loss of muscleblind-like 1 results in cardiac pathology and persistence of embryonic splice isoforms. Sci Rep. 2015;5:9042.
61. Bailey LR, Bugg D, Reichardt IM, et al. MBNL1 regulates programmed postnatal switching between regenerative and differentiated cardiac states. Circulation. 2024;149:1812-29.
62. Goers ES, Purcell J, Voelker RB, Gates DP, Berglund JA. MBNL1 binds GC motifs embedded in pyrimidines to regulate alternative splicing. Nucleic Acids Res. 2010;38:2467-84.
63. Teplova M, Patel DJ. Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1. Nat Struct Mol Biol. 2008;15:1343-51.
64. Yan Y, Zhang D, Zhou P, Li B, Huang S. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017;45:W365-73.
65. Huang SY, Zou X. A nonredundant structure dataset for benchmarking protein‐RNA computational docking. J Comput Chem. 2012;34:311-8.
66. Nithin C, Mukherjee S, Bahadur RP. A non-redundant protein-RNA docking benchmark version 2.0. Proteins Struct Funct Bioinf. 2017;85:256-67.
67. Tran H, Gourrier N, Lemercier-Neuillet C, et al. Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of muscleblind-like-1 isoforms. J Biol Chem. 2011;286:16435-46.
68. Kino Y, Washizu C, Kurosawa M, et al. Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins. Hum Mol Genet. 2015;24:740-56.
69. Gao F, Liang T, Lu YW, et al. A defect in mitochondrial protein translation influences mitonuclear communication in the heart. Nat Commun. 2023;14:1595.
